Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#4130 CHGA and DAXX/ATRX expression influence the outcome of pancreatic head neuroendocrine tumors

Introduction: In the past two years a difference between pancreatic neuroendocrine tumors (pNET) located in the head and body/tail regarding biological characteristics and clinical outcomes was described.

Conference:

Presenting Author: Amin T

Authors: Amin T, Viol F, Awwad F, Fründt T, Fraune C,

Keywords: neuroendocrine tumor, pancreatic, DAXX/ATRX, OS,

#3752 Loss of protein expression of tumor suppressor genes in neuroendocrine tumors – A tissue microarray analysis of 201 tumors from various organ sites

Introduction: Neuroendocrine tumors (NET) are a heterogenous group of tumors which differ in outcome based on their primary site. So far, data on inactivation of tumor suppressor genes in NET are mainly based on pancreatic and small intestine NET (pNET, siNET), whereas NET from other organ sites have not rigorously been analysed.

Conference:

Presenting Author:

Authors: Amin T, Viol F, Fründt T, Krause J, Fraune C,

Keywords: TMA, DAXX/ATRX, tumor suppressor, neuroendocrine tumor,

#3749 Elevated inflammatory markers are associated with poor survival after surgery for pancreatic and small intestine neuroendocrine tumors

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are a heterogenous group of neoplasms. The only curative treatment is surgery. However, predictors of survival after surgery are still missing.

Conference:

Presenting Author:

Authors: Amin T, Kailani S, Fründt T, Viol F, Stripling J,

Keywords: Neuroendocrine tumor, inflammatory marker, GEP-NET, overall survival,